Lonnel Coats Net Worth

The estimated Net Worth of Lonnel Coats is at least $5.83 Milion dollars as of 28 February 2024. Mr. Coats owns over 245,080 units of Lexicon Pharmaceuticals Inc stock worth over $1,959,452 and over the last 10 years he sold LXRX stock worth over $0. In addition, he makes $3,870,290 as President, Chief Executive Officer oraz Director at Lexicon Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Coats LXRX stock SEC Form 4 insiders trading

Lonnel has made over 17 trades of the Lexicon Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 245,080 units of LXRX stock worth $414,185 on 28 February 2024.

The largest trade he's ever made was exercising 245,080 units of Lexicon Pharmaceuticals Inc stock on 28 February 2024 worth over $414,185. On average, Lonnel trades about 30,758 units every 55 days since 2014. As of 28 February 2024 he still owns at least 1,159,439 units of Lexicon Pharmaceuticals Inc stock.

You can see the complete history of Mr. Coats stock trades at the bottom of the page.

Lonnel Coats biography

Lonnel Coats serves as President, Chief Executive Officer, Director of the Company. He has been our president and chief executive officer and a director since July 2014. Mr. Coats previously served in a series of executive leadership positions at Eisai Inc. and Eisai Corporation of North America, where he worked for 18 years before joining our company, most recently as chief executive officer from 2010 to 2014. Prior to joining Eisai, Mr. Coats spent eight years with Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, where he held a variety of management and sales positions. Mr. Coats serves as a director of Blueprint Medicines Corporation and holds a B.S. from Oakland University.

What is the salary of Lonnel Coats?

As the President, Chief Executive Officer oraz Director of Lexicon Pharmaceuticals Inc, the total compensation of Lonnel Coats at Lexicon Pharmaceuticals Inc is $3,870,290. There are no executives at Lexicon Pharmaceuticals Inc getting paid more.

How old is Lonnel Coats?

Lonnel Coats is 55, he's been the President, Chief Executive Officer oraz Director of Lexicon Pharmaceuticals Inc since 2014. There are 16 older and 2 younger executives at Lexicon Pharmaceuticals Inc. The oldest executive at Lexicon Pharmaceuticals Inc is Alan Nies, 82, who is the Independent Director.

What's Lonnel Coats's mailing address?

Lonnel's mailing address filed with the SEC is C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE, MA, 02139.

Insiders trading at Lexicon Pharmaceuticals Inc

Over the last 18 years, insiders at Lexicon Pharmaceuticals Inc have traded over $161,951 worth of Lexicon Pharmaceuticals Inc stock and bought 392,158,422 units worth $731,672,961 . The most active insiders traders include International S.C.A.Minne P..., International S.C.A.Wittouc... oraz Llc Invus, L.P.Invus Adviso.... On average, Lexicon Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $5,348,701. The most recent stock trade was executed by International S.C.A.Wittouc... on 10 May 2024, trading 57,546,100 units of LXRX stock currently worth $97,252,909.

What does Lexicon Pharmaceuticals Inc do?

corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio

Complete history of Mr. Coats stock trades at Blueprint Medicines Corp i Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc executives and stock owners

Lexicon Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Lonnel Coats,
  President, Chief Executive Officer, Director
• Praveen Tyle,
  Executive Vice President - Research and Development
• Jeffrey Wade,
  Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
• Lonnel Coats,
  CEO & Director
• Alan Main,
  Executive Vice President, Commercial Supply Operations
• Jeffrey L. Wade J.D.,
  Pres & CFO
• Dr. Alan J. Main Ph.D.,
  Exec. VP of Innovation & Chemical Sciences
• Dr. Alan J. Main,
  Exec. VP of Innovation & Chemical Sciences
• Brian T. Crum,
  VP, Gen. Counsel & Sec.
• James Tessmer,
  Vice President - Finance and Accounting
• Raymond Debbane,
  Independent Chairman of the Board
• Samuel Barker,
  Independent Director
• Frank Palantoni,
  Independent Director
• Judith Swain,
  Independent Director
• Philippe Amouyal,
  Independent Director
• Robert Lefkowitz,
  Independent Director
• Christopher Sobecki,
  Independent Director
• Alan Nies,
  Independent Director
• Dr. Robert J. Lefkowitz,
  Consultant & Independent Director
• Brian Crum,
  Vice President, General Counsel
• Dr. Craig B. Granowitz M.D., Ph.D.,
  Sr. VP & Chief Medical Officer
• Kristen L. Alexander,
  VP of Fin. & Accounting
• Chas Schultz,
  Exec. Director of Corp. Communications & Patient Advocacy
• Sam L Barker,
  Director
• Alexander A Santini,
  EVP and CCO
• Pablo Lapuerta,
  EVP and CMO
• International S.C.A.Wittouc...,
  
• Us Partners Llc Ulys, L.L.C...,
  
• Tamar D Howson,
  EVP of Bus Dev
• Barry Mills,
  Director
• Julia P Gregory,
  EVP and CFO
• James R Phd Piggott,
  SVP of Pharm Bio
• Lance K Ishimoto,
  SVP, Intellectual Property
• Clayton Stuart Rose,
  Director
• Public Equities, L.P.Artal ...,
  
• Public Equities, L.P.Artal ...,
  
• International S.C.A.Minne P...,
  
• Diane E. Sullivan,
  Director
• Thomas Garner,
  SVP, Chief Commercial Officer
• Arthur T Sands,
  Pres & CEO
• John Northcott,
  VP, Marketing, Comm Strategy
• Cv Ulys, L.L.C.Debbane Raym...,
  
• International S.C.A.Minne P...,
  
• Brian P Zambrowicz,
  EVP, Chief Scientific Officer
• Llc Invus, L.P.Invus Public...,
  
• International S.C.A.Invus, ...,
  
• Kathleen M Wiltsey,
  Director
• Llc Invus, L.P.Invus Adviso...,
  
• Philip M Brown,
  SVP Clinical Development
• Steven Alan Tragash,
  VP, Corporate Affairs
• Llc Invus, L.P.Invus Adviso...,
  
• Ajay Bansal,
  EVP Corp Dev and CFO
• Kristen Alexander,
  VP, Finance and Accounting
• C.V. Invus,
  Director
• Craig B Granowitz,
  SVP, Chief Medical Officer
• Kenneth B. Kassler Taub,
  SVP, Regulatory & QA
• Wendy Mc Dermott,
  VP, Human Resources
• Kiernan Seth,
  VP, Chief Commercial Officer
• Michael Exton,
  Chief Executive Officer
• Brian Corrigan,
  SVP, Regulatory & QA